title: A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South.
abstract: BACKGROUND
  EGFR mutated lung cancer represents a subgroup with distinct clinical presentations, prognosis, and management requirements. We investigated the survival, prognostic factors, and real-world treatment of NSCLC patients with EGFR mutation in clinical practice.
  
  
  METHODS
  A retrospective review of all specimens sent for EGFR analysis from December 2009 to September 2015 was performed. Patient demographics, specimen type, EGFR mutation status/type, stage at diagnosis, treatment, response rate, and survival data were recorded.
  
  
  RESULTS
  27/334 (8%) patient specimens sent for EGFR testing tested positive for a sensitising EGFR mutation. The median age was 65 years (40-85 years). Exon 19 deletion represented the most commonly detected alteration, accounting for 39% (n = 11). First-line treatment for those with Exon 18, 19, or 21 alterations (n = 24) was with an EGFR tyrosine kinase inhibitor (TKI) in 79% (n = 19). Objective response rate among these patients was 74% and median duration of response was 13 months (range 7-35 months).
  
  
  CONCLUSIONS
  The incidence of EGFR mutation in our cohort of NSCLC is 9% which is consistent with mutation incidence reported in other countries. The rate of EGFR mutation in our population is slightly below that reported internationally, but treatment outcomes are consistent with published data. Real-world patient data have important contributions to make with regard to quality measurement, incorporating patient experience into guidelines and identifying safety signals.
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland. deirdre.kelly.2108@gmail.com.
authors.forename: D
authors.identifier: http://orcid.org/0000-0002-4853-5712
authors.initials: D
authors.lastname: Kelly
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: L
authors.initials: L
authors.lastname: Mc Sorley
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: E
authors.initials: E
authors.lastname: O'Shea
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: E
authors.initials: E
authors.lastname: Mc Carthy
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: S
authors.initials: S
authors.lastname: Bowe
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: C
authors.initials: C
authors.lastname: Brady
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: J
authors.initials: J
authors.lastname: Sui
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: M A
authors.initials: MA
authors.lastname: Dawod
authors.affiliation: Department of Pathology, Cork University Hospital, Cork, Ireland.
authors.forename: O
authors.initials: O
authors.lastname: O'Brien
authors.affiliation: Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.
authors.forename: D
authors.initials: D
authors.lastname: Graham
authors.affiliation: Department of Pathology, Cork University Hospital, Cork, Ireland.
authors.forename: J
authors.initials: J
authors.lastname: McCarthy
authors.affiliation: Department of Pathology, Cork University Hospital, Cork, Ireland.
authors.forename: L
authors.initials: L
authors.lastname: Burke
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: D
authors.initials: D
authors.lastname: Power
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: S
authors.initials: S
authors.lastname: O'Reilly
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: R M
authors.initials: RM
authors.lastname: Bambury
authors.affiliation: Department of Medical Oncology, Cork University Hospital, Mercy University Hospital Cork, University Hospital Kerry, Tralee, County Kerry, Ireland.
authors.forename: D O
authors.initials: DO
authors.lastname: Mahony
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D015331:Cohort Studies; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D015994:Incidence; D007494:Ireland / Q000453:epidemiology; D008175:Lung Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR mutated; Erloitinib; HSE South; Incidence; Non-small cell lung cancer